导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.75% | 1558/4773 |
| 近一周 | -1.21% | 1815/5465 |
| 近一月 | -8.24% | 4859/5421 |
| 近一季 | -18.44% | 4762/5231 |
| 近半年 | -0.75% | 1574/4920 |
| 近一年 | 7.67% | 1441/4394 |
| 近两年 | 113.85% | 485/2954 |
| 近三年 | 67.74% | 378/2253 |
| 成立以来 | 34.69% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.62% 1887/4961 |
35.15% 926/5312 |
- - |
- - |
| 2025 | 48.80% 510/4813 |
-1.58% 2697/3635 |
3.25% 1084/4076 |
47.67% 436/4524 |
-0.84% 2680/4813 |
| 2024 | 14.73% 1016/3463 |
-3.66% 1536/2808 |
-6.36% 1922/3014 |
27.93% 204/3129 |
-0.59% 1470/3463 |
| 2023 | -18.07% 1781/2656 |
2.19% 1416/2280 |
-6.95% 1747/2385 |
-8.96% 1756/2515 |
-5.35% 1329/2655 |
| 2022 | -28.06% 1523/2207 |
-19.08% 1428/1919 |
5.49% 892/2016 |
-17.64% 1625/2113 |
2.33% 970/2208 |
| 2021 | 12.07% 388/1822 |
-6.46% 1003/1255 |
25.15% 96/1330 |
-6.35% 919/1466 |
2.23% 651/1822 |
| 2020 | - - |
- - |
- - |
- - |
14.74% 252/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方创业板ETF联接E VS. 长安沪深300非周期A(740101) |